指南与共识神经肿瘤

cIMPACT-NOW更新12:细化IDH突变胶质瘤的病理风险分层与分级

cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas.
指南 / 共识 · Neuro Oncol · 2026-01-01

cIMPACT-NOW工作组综述IDH突变胶质瘤文献,提出改进病理风险分层与分级的建议,尤其关注CNS WHO 2级与3级交界。PDGFRA扩增与IDH突变星形细胞瘤高度侵袭行为相关,符合CNS WHO 4级;PIK3突变、EGFR改变、MYCN扩增及特定RB通路改变等与中等风险相关,符合CNS WHO 3级。建议将每2.4 mm²≥3个核分裂象作为CNS WHO 3级标准。

要点

  • PDGFRA扩增的IDH突变星形细胞瘤按CNS WHO 4级处理。
  • PIK3突变、EGFR改变、MYCN扩增及RB通路特定改变符合CNS WHO 3级。
  • 每2.4 mm²≥3个核分裂象可考虑作为CNS WHO 3级标准。

核心结论

  • 基于证据的风险分层与分级标准可改善IDH突变胶质瘤的临床决策指导。

研究设计与样本

  • cIMPACT-NOW工作组对IDH突变胶质瘤文献进行综述,评估病理风险分层与分级改进机会。

主要发现

  • PDGFRA扩增与IDH突变星形细胞瘤高度侵袭行为相关,符合CNS WHO 4级。
  • PIK3突变、EGFR改变、MYCN扩增及特定RB通路改变与中等风险相关,符合CNS WHO 3级。
  • G-CIMP-low或A_IDH_HG的DNA甲基化特征符合CNS WHO 3级或4级,取决于其他分级标准。
  • 每2.4 mm²≥3个核分裂象可考虑作为CNS WHO 3级标准。
  • 未发现改善IDH突变且1p/19q共缺失少突胶质瘤分级的特征。

关键数值与推荐

  • PDGFRA扩增的IDH突变星形细胞瘤符合CNS WHO 4级。
  • PIK3突变、EGFR改变、MYCN扩增、CDK4/CDK6/CCND2扩增、RB1纯合缺失或突变、CDKN2A突变符合CNS WHO 3级。
  • 每2.4 mm²≥3个核分裂象可考虑为CNS WHO 3级标准。
  • G-CIMP-low或A_IDH_HG甲基化特征符合CNS WHO 3级或4级。

临床怎么用

  • 对IDH突变星形细胞瘤评估PDGFRA扩增以识别CNS WHO 4级行为。
  • 结合PIK3突变、EGFR改变、MYCN扩增及RB通路改变等遗传学特征进行CNS WHO 3级风险分层。
  • 可考虑将每2.4 mm²≥3个核分裂象作为CNS WHO 3级的分级标准。

局限性

  • 综述未发现改善IDH突变且1p/19q共缺失少突胶质瘤分级的特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A working group of cIMPACT-NOW evaluated the literature on IDH-mutant gliomas for opportunities to improve pathology-based risk stratification and grading, especially at the interface of CNS WHO grades 2 and 3, since therapeutic decisions depend on risk assessment for clinical management. The group also evaluated newly described IDH-mutant glioma subgroups and considered multidisciplinary aspects of therapeutic decision-making. PDGFRA amplification was associated with highly aggressive clinical behavior of IDH-mutant astrocytomas, consistent with CNS WHO grade 4. Other genetic alterations associated with intermediate risk and most consistent with CNS WHO grade 3 included PIK3 mutations; EGFR alteration; MYCN amplification; and specific retinoblastoma pathway alterations, including CDK4, CDK6, and CCND2 amplification, RB1 homozygous deletion or mutation, and mutation of CDKN2A. DNA methylation signatures of G-CIMP-low or A_IDH_HG were consistent with CNS WHO grade 3 or 4, depending upon other grading criteria. We suggest a mitotic count of ≥3 per 2.4 mm2 could be considered as a CNS WHO grade 3 criterion. Our review did not uncover features to improve the grading of oligodendroglioma, IDH-mutant and 1p/19q-codeleted, although CNS WHO grade 3 tumors with elevated mitotic rates, yet lacking necrosis, microvascular proliferation, CDKN2A/B homozygous deletion, and MRI contrast enhancement, may be associated with extended survival. Implementing evidence-based criteria for risk stratification and grading will improve guidance for clinical decision-making. The IDH-mutant diffuse gliomas, including IDH-mutant astrocytomas and IDH-mutant and 1p/19qcodeleted oligodendrogliomas, were first recognized by the WHO Classification of Tumours in 2016, when they were separated from glioblastoma, IDH-wildtype, and other molecular forms of diffuse gliomas that have differing clinical outcomes and therapeutic approaches. There is widespread agreement that the criteria for grading IDH-mutant gliomas, which are highly relevant to patient care, are not optimal for predicting patient outcome. cIMPACT-NOW is a consortium that provides practical recommendations to improve the diagnosis and classification of CNS tumors and has here provided new evidence-based recommendations for grading criteria for IDH-mutant gliomas.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Brat DJ, Aldape K, French PJ, et al. cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas. Neuro Oncol. 2026. PMID: 42152226. doi:10.1093/neuonc/noag108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。